Liraglutide remains a vital research tool for studying GLP-1 pathways and investigating the mechanisms underlying incretin-based therapies. As one of the first once-daily GLP-1 receptor agonists, liraglutide has been extensively studied and continues to be used in research applications.
Liraglutide is a GLP-1 analog with a fatty acid moiety that promotes albumin binding and extends half-life to approximately 13 hours, enabling once-daily dosing. It was the first GLP-1 receptor agonist approved for obesity (Saxenda) in addition to type 2 diabetes (Victoza). The LEAD and SCALE clinical trials established the efficacy of liraglutide for glycemic control and weight loss.
Research applications of liraglutide include studies of GLP-1 receptor signaling, investigations of appetite regulation and energy homeostasis, and exploration of the cardiovascular and renal effects of GLP-1 agonism. Liraglutide is also used as a comparator in studies of newer GLP-1 receptor agonists, providing a benchmark for efficacy and safety.
Beyond metabolic research, liraglutide is being investigated for potential applications in neurodegenerative disorders, based on evidence that GLP-1 receptor activation may have neuroprotective effects. These studies are exploring the potential of GLP-1 agonists for conditions including Alzheimer's disease and Parkinson's disease.
At PeptideHub, we provide high-quality liraglutide for research applications, with comprehensive analytical documentation. Our liraglutide is suitable for in vitro and in vivo studies, providing researchers with reliable material for investigating GLP-1 biology and developing next-generation therapeutics.